{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-098205","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.267651+00:00","generated_at":"2026-05-17T03:55:27.284642+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"InMed appoints Neil Klompas to board, effective October 9, 2025","bullets":["Neil Klompas, CPA, CA, appointed to Board; board size increased to 5 members.","Klompas brings 30+ years experience; was President/COO and CFO at Zymeworks (NASDAQ: ZYME), led 2017 IPO.","Currently CEO of Augerex Life Science Corp, serves on boards of NervGen Pharma (TSXV: NGEN) and HTuO Biosciences.","He will receive standard non-employee director compensation: US$50k annual retainer plus potential committee fees.","No related party transactions or family relationships with any director or officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-098205","json":"https://secwatch.observer/filing/0001213900-25-098205.json","markdown":"https://secwatch.observer/filing/0001213900-25-098205.md","text":"https://secwatch.observer/filing/0001213900-25-098205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/0001213900-25-098205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390025098205/ea0260877-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:55:27.284642+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}